Meeting
2022 ASCO Genitourinary Cancers Symposium
Outcomes according to histological variants of urothelial carcinoma after neoadjuvant chemotherapy in the GETUG-AFU V05 VESPER trial.
Authors
Yves Allory
Institut Curie, St-Cloud, France
Yves Allory , Stephane Culine , Clémentine Krucker , Valentin Harter , Christian Pfister
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Urothelial Carcinoma
Track
Urothelial Carcinoma
Sub Track
Translational Research, Tumor Biology, Biomarkers, and Pathology
Citation
J Clin Oncol 40, 2022 (suppl 6; abstr 533)
DOI
10.1200/JCO.2022.40.6_suppl.533
Abstract #
533
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2012 Genitourinary Cancers Symposium
Pathologic down-staging and complete pathologic response with gemcitabine and cisplating neoadjuvant chemotherapy for muscle-invasive urothelial carcinoma of the bladder.
First Author: Sarah P. Psutka
Poster
2023 ASCO Genitourinary Cancers Symposium
FDG PET-CT imaging in assessing interim response to neoadjuvant cisplatin-based chemotherapy (NAC) in muscle invasive bladder cancer (MIBC): A prospective study.
First Author: Srikala S. Sridhar
Poster
2019 ASCO Annual Meeting
Defects in DNA repair genes and long-term survival in cisplatin-based neoadjuvant chemotherapy for muscle invasive bladder cancer (MIBC).
First Author: Benjamin Miron
Poster
2013 ASCO Annual Meeting
Randomized phase III trial of neoadjuvant chemotherapy (NAC) with methotrexate, doxorubicin, vinblastine, and cisplatin (MVAC) followed by radical cystectomy (RC) compared with RC alone for muscle-invasive bladder cancer (MIBC): Japan Clinical Oncology Group study, JCOG0209.
First Author: Hiroshi Kitamura